A single-center experience in parenchyma-sparing surgical treatment of malignant pleural mesothelioma
The role of surgery in malignant pleural mesothelioma remains controversial.
The role of surgery in malignant pleural mesothelioma remains controversial, particularly after the negative results of the MARS 1 and 2 trials. Lung-sparing cytoreductive procedures such as extended pleurectomy/decortication (eP/D) are increasingly adopted in high-volume centers, but real-world outcomes within multimodality pathways vary widely. This study analyzes our Institutional experience with parenchyma-sparing surgery in a trimodal strategy, focusing on perioperative outcomes, recurrence patterns, and survival, with particular attention to the prognostic impact of nodal status. A total of 102 patients were included. Median disease-free survival (DFS) was 11.7 months and median overall survival (OS) was 28.0 months. Nodal metastasis was associated with significantly worse OS.
This study provides real-world outcomes of parenchyma-sparing surgery for malignant pleural mesothelioma, emphasizing the prognostic importance of nodal status within a trimodal treatment approach.
Evidence level: Sejtvonalas. Laboratóriumi sejtekben vizsgálták.
Related signals
- Moving Beyond Morphology: Toward a Morpho‑Molecular Classification of Pleural Mesothelioma
- Comparison of Survival by Multimodal Treatment Regimen Among Malignant Pleural Mesothelioma Patients in an Integrated Health System
- Systemic Treatments for Unresectable Pleural Mesothelioma: A Review of the Literature
- Prognostic impact of somatic mutations among patients with pleural and peritoneal mesothelioma
- Tumor Treating Fields (TTFields) for Pleural Mesothelioma